Subject Index

A

Acoustic neuroma

epidemiological evidence of allergic disorders and cancer occurrence, 62–63

See also Brain tumors; Neuroblastoma

Activation-induced deaminase (AID)
in CSR, 15–18
replication protein A (RPA) binding to, 18

Acute leukemia

acute lymphoblastic leukemia (ALL), 83, 126–127
acute myelogenous leukemia (AML), 83

See also Chronic leukemia

Adenocarcinoma

mast cells in, 145

See also Angiogenesis

Affinity maturation, 42–43
in germinal centers (GC), 37–38

See also High-affinity IgE antibodies

Airway tissue remodeling

airway smooth muscle (ASM) function, 142–143
mast cells and, 142–143

Allergen-associated molecular patterns

(AAMP), 238–242

See also Pathogen-associated molecular patterns (PAMPs); Tumor-associated molecular patterns

AllergoOncology

definition, 8
history, 4–8
IgE historical aspects and, 6–8

See also Allergy; IgE in cancer therapy

AllergoOncology (epidemiological evidence of allergic disorders and cancer occurrence), 47

methods, 48
results, 48–52

bladder cancer, 67
bone cancer, 68
colorectal cancer, 64–65
esophageal cancer, 67
lung cancer, 52–56
pancreatic cancer, 56–60
reproductive cancers, 65–66
skin cancer, 68
stomach cancer, 67
tumors of brain and nervous system, 60–64

AllergoOncology (epidemiological evidence of allergic disorders and hematopoietic malignancies), 79–122
cancers immunoregulatory mechanism, 81
cancers incidence and incidence rates, 80
case–control studies, 81
cohort studies, 81
HL, 114–115
NHL, 98–111
Hodgkin lymphoma (HL), 112–115
leukemias, 82–96
methods of review, 81–82
non-Hodgkin lymphoma (NHL), 96–112
plasma cell malignancies,
113, 116–122
potential mechanistic interactions between allergy/atopy associated with hematopoietic cancers development, 122
CD23 expression stabilization by IgE, 124–126
IgE/allergy-mediated enhancement of antitumor immunity, 123–124
IgE-mediated allergies and B-cell NHL, 126–128
Allergy
  cancer and, see AllergoOncology
  definition, 4
  history, 2–3
  mast cells in, 137–143
  Pirquet's allergy, 3
Anaphylaxis
  anti-tumor, 166–167
  IgE and anaphylactic reaction, 231–232
Angiogenesis
  mast cells in cancer, 143–144
  See also AllergoOncology
Antibodies generation
  high-affinity, 37–44
    generation pathways, 41–44
    sequential switching to IgE in mice and humans, 40
  low-affinity, 37–39
    class switching, 39
    direct switching from IgM to IgE, 38
  See also Immunoglobulins (Ig)
Antibody-dependent cell-mediated cytotoxicity (ADCC)
  IgE, 164
  IgG, 163
  MOv18 IgE-mediated, 197–199
  See also IgE in cancer therapy
Antibody-dependent cell-mediated phagocytosis (ADCP), 164
MOv18 IgE-mediated, 199–202
trastuzumab-like IgE-mediated, 202
Antibody-secreting plasma, 26
Antigen-presenting cells (APC) IgE
  cancer therapy, 164–165
  effector cells in cancer and, 193–194
  mast cells as, 141–142
  See also Crosslinking (antigens)
Anti-tumor
  anaphylaxis, 166–167
  IgE-mediated anti-tumor responses
    IgE effector cell responses, 185–206
    mouse IgE-induced tumor protection, 217–218
  immunity
    IgE/allergy-mediated enhancement of antitumor immunity (hematopoietic malignancies), 123–124
    Th2-mediated anti-tumor immunity, 255–268
  See also IgE adjuvant effect (tumor vaccination); IgE in cancer therapy
Asthma
  acoustic neuroma and, 62–63
  basal cell carcinoma, 67
  brain tumor, 63
  glioma, 60–61
  meningioma and, 60–62
  colorectal cancer, 64–65
  esophageal cancer, 67
  leukemia and
    ALL, 83
    AML, 83
    CML, 83
  lung cancer, 52–53, 55–56
  multiple myeloma, 116
  neuroblastoma and, 64
  pancreatic cancer, 56–60
  reproductive cancers, 65–66
  stomach cancer, 67
  urothelial cancer, 67
  See also Eczema; Hay fever
Atopic dermatitis, 68
  See also Melanoma
B
  B cell interactions
    B-cell NHL, 96–97, 112, 126
    high-affinity IgE antibodies generation
      IgE⁺ cells found outside GC in both T/B monoclonal and wild-type mice (experimental evidence), 42
      T-B cells interaction, 37–38
    low-affinity IgE antibodies generation and B cells interaction, 38
      direct switching aspects, 38–39
      Th2-mediated and anti-tumor immunity, 266
    See also T cell interactions
  B cell receptor (BCR), 22
  Basal cell carcinoma
    asthma and, 67
    See also AllergoOncology
  Basophils
    IgE effector cells in cancer and, 190
    IgE-mediated effector cell responses (experimental evidence), 203–204
  Bladder cancer
    epidemiological evidence of allergic disorders and cancer occurrence, 67
    See also AllergoOncology
  Blood cancer, see AllergoOncology
    (epidemiological evidence of allergic disorders and hematopoietic malignancies)
Bone cancer, 68

Brain tumors
  epidemiological evidence of allergic disorders and cancer occurrence, 60–63
  See also Glioma; Meningioma

Breast cancer
  epidemiological evidence of allergic disorders and cancer occurrence, 65–66
  mast cells in, 145

C
Cancers
  allergy and, see AllergoOncology
  epidemiological evidence of allergic disorders and cancer occurrence, 52–68
  hematopoietic malignancies, 79–122
  IgE in cancer therapy, see IgE in cancer therapy
  IgG in cancer therapy, 164, 168
  IgE advantages over IgG, 162–165
  Th2-mediated anti-tumor immunity, 265–266
  See also Anti-tumor
CD20 antibody
  IgE (chimeric IgE targeting human CD20), 174–175
  IgG, 174

CD23 antibody
  expression stabilization by IgE (hematopoietic malignancies), 124–126
  IgE adjuvanticity in tumor vaccination (FcεRII), 223–225
  IgE-mediated anti-tumor responses (pancreatic cancer case), 205
  low affinity IgE receptor (FcεRII), 188
  membrane-bound form (mCD23), 20–22
  negative feedback function, IgE expression influence by, 20–22
  soluble form (sCD23), 20–22

CD4+ T cells
  Th1 and Th2 paradigm in tumor biology, 256–257
  See also Th2-mediated anti-tumor immunity

CD8 antibody
  CD8+ T cells (Tc2 cells), 267–268
  rat/human chimeric IgE specific for murine, 169–170
  Cervical cancer (epidemiological evidence of allergic disorders and cancer occurrence), 66

Chemokines
  migratory plasmablasts and, 27
  chemokine ligand (CXCL), 27
  chemokine receptor (CXCR)
  See also B cell interactions

Chimeric ovarian carcinoma antigen-specific MOv18
  in IgE-mediated anti-tumoral responses, 195
  See also Effector cell responses

Chronic leukemia
  lymphocytic leukemia (CLL), 96
  myelogenous leukemia (CML), 83
  See also Acute leukemia

Class switch recombination (CSR)
  activation-induced deaminase (AID) in, 15–18
  cytokine signaling and, 15
  germline transcription (GLT) and, 16–18
  interleukins and
    IL-4, 15, 17
    IL-6/10/21, 18
  reduced class switch frequency to IgE locus, 14–18

Class switching to IgE, 39

Cleavage-polyadenylation specificity factor (CPSF), 25

CNS tumors, see Nervous system tumors

Colorectal cancer
  epidemiological evidence of allergic disorders and cancer occurrence, 64–65
  mast cells in, 145
  murine and mouse/human chimeric IgE specific for antigenic determinant on carcinoma cells surface, 170–171

Connective tissue mast cells (CTMC), 138–139
  See also Mucosal mast cells (MMC)

Contact hypersensitivity (CHS), 139

Crosslinking (antigens)
  IgE synthesis aspects, 235–238
  immunoregulation aspects, 232–234
  See also Allergen-associated molecular patterns (AAMP); Tumor-associated molecular patterns
Cytokines
  class switch recombination (CSR)
    and, 15
  Th2 cytokines and anti-tumor immunity,
    257–260
  See also Interleukins (IL)
Cytoplasmic domain (mIgE), 22

D
Dendritic cells (DCs)
  mast cells and, 139–141
Dermatitis
  atopic, 68
  See also Eczema

E
Eczema
  cancer and
    acoustic neuroma, 61–63
    glioma, 60–61
    lung cancer, 55–56
    meningioma, 60–62
    neuroblastoma, 64
    pancreatic cancer, 58–59
    skin cancer and, 68
  See also Asthma; Hay fever
Effector cell responses
  IgE effector cells in cancer
    antigen-presenting cells,
      193–194
    basophils, 190
    eosinophils, 192–193
    macrophages, 191–192
    mast cells, 190
    missing activation signals and tumor
      growth, 189–194
    monocytes, 191–192
    natural killer cells, 193
  IgE–FcεRI complex, 186–188
  IgE–FcεRII complex, 188
  IgE-mediated anti-tumor responses
    chimeric ovarian carcinoma
      antigen-specific MOv18 IgE
        effector cells, 195
    MOv18, 195–202
    pancreatic cancer case (CD23), 205
    PBMC and monocyte activities, 194
    stimulation of mast cells, basophils
      and eosinophils (experimental
        evidence), 203–204
    trastuzumab like IgE, 202–203
    MOv18 IgE-mediated responses, 196
    chimeric ovarian carcinoma, 195
tumor killing mechanisms (ADCC),
  197–199
  tumor killing mechanisms (ADCP),
  199–202
Endometrial cancer (epidemiological evidence
  of allergic disorders and cancer
  occurrence), 66
Eosinophils
  IgE effector cells
    in cancer, 192, 193
    responses (experimental evidence),
      203–204
  Th2-mediated anti-tumor immunity,
    262–264
Epidemiological evidence
  allergic disorders and cancer occurrence,
  see AllergoOncology
    (epidemiological evidence of
      allergic disorders and cancer
      occurrence)
  hematopoietic malignancies, see
    AllergoOncology (epidemiological
      evidence of allergic disorders and
      hematopoietic malignancies)
Epsilon-binding protein (e-BP)
  galectin-3, 189
  See also Fc epsilon (Fcε) receptors
Epsilon-HC gene, 26
  See also Polyadenylation
Esophageal cancer
  cigarette smoking and, 67
  epidemiological evidence of allergic
    disorders and cancer
    occurrence, 67
  Extracellular membrane-proximal domain
    (EMPD)
  mIgE, 22

F
Fc epsilon (Fcε) receptors
  adjuvanticity in tumor vaccination
    FcεRI humanized mice and human IgE
      in tumor vaccination, 225–226
    IgE–FcεRI complex, 223–224
    IgE–FcεRII complex, 118–119
    high affinity (FcεRI), 185–186
    low affinity (FcεRII), 188
  See also Galectin-3
Folate binding protein
  mouse/human chimeric IgE specific for
    human folate binding protein,
      171–173
  See also IgE in cancer therapy
Galectin-3
tumor cell death and, 189
See also Fc epsilon (Fcε) receptors

Genital cancer
epidemiological evidence of allergic disorders and cancer occurrence, 66
See also Reproductive cancers

Germinal centers (GC)
affinity maturation and, 37–38
IgE+ cells found outside GC in both T/B monoclonal mice and wild-type mice
high-affinity IgE antibodies generation (experimental evidence), 42
See also High-affinity IgE antibodies

Germline transcription (GLT), 16–18

Glioma
epidemiological evidence of allergic disorders and cancer occurrence, 60–61
See also Brain tumors
Glycoprotein 36 (gp36)
MMTV, 168–169
See also IgE in cancer therapy

Herpes simplex virus type 1 (HSV-1)
See also Cell-bound antibodies

Herpes simplex virus type 2 (HSV-2)
See also Cell-bound antibodies

HEV
See also Allergen

HER2/neu
anti-HER2/neu IgE response, 175
engineered IgE specific for human, 173–174

High-affinity Fc epsilon (Fcε) receptors
FcεRI (IgE-FcεRI complex), 185
adjuvanticity in tumor vaccination, 218–219
FcεRI humanized mice and human IgE in tumor vaccination, 225–226
See also Low-affinity Fc epsilon (Fcε) receptors

High-affinity IgE antibodies, 37–38
generation pathways
IgE antibodies undergoing somatic hypermutation and affinity maturation, 42–43
IgE+ cells found outside germinal centers in both T/B monoclonal mice and wild-type mice, 42
IgG1+ B cells generating IgE antibodies by sequential switching, 43
interleukin-21 inhibiting sequential switching of IgG1+ cells to IgE, 43–44
sequential switching to IgE in mice and humans, 40
summary of findings, 41
somatic hypermutation (SHM), 37
T–B cell interactions, 37–38
versus low-affinity IgE antibodies, 37–38
See also Low-affinity IgE antibodies

Hodgkin lymphoma (HL)
alergic disorders and epidemiological evidence of, 112–115
case–control studies, 114–115
mast cells in, 145
See also Non-Hodgkin lymphoma (NHL)

HS1-associated protein X-1 (HAX-1), 24

Human IgE
chimeric IgE
specific for antigenic determinant on colorectal carcinoma cells surface, 170–171
specific for human folate binding protein, 171–173
specific for murine CD8, 169–170
targeting human CD20, 174–175
FcεRI humanized mice and human IgE in tumor vaccination, 225–226
MVA as resource for human therapy and recombinant protein expression, 221
Human IgE (cont.)
transgenic mice use for IgE receptor involvement and human IgE implementation, 222
See also Mouse IgE
Human tumors
mast cells in cancer, 145–147
See also Cancers
Humoral immunological memory, 26
See also Plasmablasts
Hypermutation
somatic (SHM), 37
See also High-affinity IgE antibodies

IgE, 160
adjuvant effect, see IgE adjuvant effect (tumor vaccination)
AllergoOncology history and, 4–8
anaphylactic reaction and, 231–232
antibodies generation
high-affinity, 37–44
low-affinity, 37–39
cancer therapy, see IgE in cancer therapy
crosslinking (antigens)
IgE synthesis aspects, 235–238
immunoregulation aspects, 232–234
IgE-FcεRI complex
adjuvanticity in tumor vaccination, 223–224
effector cell responses, 185–188
IgE-FcεRII complex
adjuvanticity in tumor vaccination, 218–219
effector cell responses, 188
hematopoietic malignancies and
CD23 expression stabilization by IgE, 124–126
IgE/allergy-mediated enhancement of antitumor immunity, 123–124
IgE-mediated allergies and B-cell NHL, 126–128
identification (1967), 4
membrane, see Membrane IgE (mIgE)
molecular mechanisms, 13–28
CD23 negative feedback function, 20–22
Ig mRNA processing, 24–26
IgE plasmablasts contribution to long-lived plasma cell pool, 26–27
impaired splicing and polyadenylation restricting mature mIgE transcript generation, 24–26
mIgE antigen receptor function and in vivo IgE synthesis, 22–24
reduced CSR to IgE locus, 14–18
serum IgE half life, 18–20
receptors
high-affinity (FcεRI), 185–188,
low-affinity (FcεRII), 188, 222
structure and binding properties, 161–162
targets
AAMP, 238–242
TAMP, 242, 244
See also Human IgE; Mouse IgE
IgE adjuvant effect (tumor vaccination), 215
IgE-FcεRI adjuvanticity
FcεRI humanized mice and human IgE, 225–226
in tumor vaccination, 223–224
mouse IgE-induced tumor protection, 218–226
transgenic mice use for IgE receptor involvement and human IgE implementation, 222
Vaccinia virus and MVA as cell killing agents coupled to IgE loading, 220–221
mouse membrane-bound IgE implementation by recombinant MVA, 224–225
IgE in cancer therapy, 159
function and relevance in cancer therapy, 162–165
IgE effector cells, see Effector cell responses
local anti-tumor anaphylaxis, 166–167
passive cancer immunotherapy (using tumor-specific IgE)
chimeric IgE targeting human CD20, 174–175
engineered IgE specific for human HER2/neu, 173–174
mouse/human chimeric IgE specific for human folate binding protein, 171–173
murine and mouse/human chimeric IgE specific for antigenic determinant on colorectal carcinoma cells surface, 170–171
murine IgE specific for gp36 of MMTV, 168–169
rat/human chimeric IgE specific for murine CD8, 169–170
Th2-mediated and anti-tumor immunity, 265–266
tumor-specific monoclonal IgE generation
endogenous IgE response via mimotope vaccination, induction of, 175–176
monoclonal and recombinant IgE development, 167–168
tumor-specific IgE for passive cancer immunotherapy, 168–175
See also Fc epsilon (Fcε) receptors; Galectin-3; IgE adjuvant effect (tumor vaccination)

IgG, 14, 160
high-affinity IgE antibodies generation aspects (sequential switching to IgE in mice and humans), 40
IL-21 inhibiting switching of IgG1+ to IgE, 43–44
IgG1+ B cells generating IgE, 43
Ig mRNA processing, 25
in cancer therapy, 164, 168
advantages of IgE therapy over IgG, 162–165
Omalizumab therapy, 162–163
Th2-mediated anti-tumor immunity, 265–266
serum, 19–20
See also IgE; Trastuzumab-like IgE

Immunoglobulins (Ig), 159–160
A (IgA), 25, 160
D (IgD), 160
E, see IgE
G, see IgG
M (IgM), 160
high-affinity IgE antibodies generation aspects (sequential switching to IgE in mice and humans), 40
Ig mRNA processing, 25
low-affinity IgE antibodies generation aspects (direct switching from IgM to IgE), 38–39
mRNA processing membrane form, 24–26
secreted form, 24–26
serum
IgE, 18–20
IgG, 19–20
Y (IgY), 13
See also

Interleukins (IL)
class switch recombination (CSR) and IL-4, 15, 17
IL-6/10/21, 18
IL-21 inhibiting sequential switching of IgG1+ cells to IgE (high-affinity IgE antibodies generation), 43–44
Th2 cytokines and anti-tumor immunity
IL-13, 258, 260
IL-24, 258, 261
IL-25, 258, 261–262
IL-4, 257–260

L
Leukemias
acute, 83
ALL, 83, 126–127
AML, 83
allergic disorders and epidemiological evidence of, 84–96
case-control, 86–95
cohort studies, 84–85
chronic
CLL, 96
CML, 83
lymphocytic, 83
myelogenous, 83
See also AllergoOncology (epidemiological evidence of allergic disorders and hematopoietic malignancies)

Low-affinity Fc epsilon (Fcε) receptors
adjuvanticity in tumor vaccination (IgE-FcεRI complex), 223–224
FcεRII (CD23), 188
See also CD23 antibody; High-affinity Fc epsilon (Fcε) receptors

Low-affinity IgE antibodies
B cells interactions and, 38
generation
class switching, 39
direct switching from IgM to IgE, 38
versus high-affinity IgE antibodies, 37–38
See also High-affinity IgE antibodies

Lung cancer
epidemiological evidence of allergic disorders and cancer occurrence, 52–56
mast cells in, 145

Lymphocytic leukemias, 83
potential mechanistic interactions between allergy/atopy associated with hematopoietic cancers development, 122
See also Myelogenous leukemias
Subject Index

Lymphoid malignancy associations, atopy and, 122

Lymphoma
  Hodgkin lymphoma (HL), 112–113
  mast cells in, 145
  non-Hodgkin lymphoma (NHL), 96–112

M
  Macrophages
    alternatively activated (Th2-mediated anti-tumor immunity), 264–265
  IgE effector cells in cancer and, 191–192
  Mast cells (MCs), 137
    as APCs, 141–142
    in allergy
      airway tissue remodeling and, 142–143
      MCs and dendritic cells, 139–141
      MCs and T cells and, 141–142
      MCs subsets, 138–139
    in cancer, 143
      adaptive immune responses to tumors, regulation of, 148, 150
      angiogenesis, 143–144
      human tumors, 145–147
      IgE-mediated effector cell responses, 190, 203–204
      tumor growth or rejection (MC mediators), 145, 148
    subsets
      connective tissue (CTMC), 138–139
      mucosal (MMC), 138–139
      Th2-mediated and anti-tumor immunity, 266–267

Melanoma, 68
  See also Atopic dermatitis

Membrane IgE (mIgE)
  antigen receptor function and in vivo IgE synthesis and, 22–24
  structural features
    cytoplasmic domain, 22
    EMPD, 22
    transmembrane domain, 22
  transcript generation restriction by impaired splicing and polyadenylation, 24, 26
  See also B cell receptor (BCR)

Meningioma
  epidemiological evidence of allergic disorders and cancer occurrence, 60–62
  See also Glioma

Migratory plasmablasts, 26

chemokine ligand (CXCL) and receptors (CXCR), 27

See also IgE

Mimotopes, 232
  vaccination, 175–176
  See also IgE in cancer therapy; Paratopes

Modified vaccinia virus Ankara (MVA)
  as cell killing agents coupled to IgE loading in mice, 220–221
  as resource for human therapy and recombinant protein expression, 221–222
  mouse membrane-bound IgE implementation by recombinant MVA, 224–225
  See also Vaccinia virus (VV)

Monocytes, IgE effector cells in cancer and, 191–192

Mouse IgE
  tumor growth and improved mice survival, 216
  cell types involved in IgE-induced tumor protection, 217–218
  FcεRI humanized mice and human IgE in tumor vaccination, 225–226
  IgE adjuvant effect (tumor vaccination), 218–219
  IgE-FcεRI adjuvanticity in tumor vaccination, 223–224
  mouse membrane-bound IgE implementation by recombinant MVA, 224–225
  MVA as resource for human therapy and recombinant protein expression, 221–222
  transgenic mice use for IgE receptor involvement and human IgE implementation, 222
  Vaccinia virus and MVA as cell killing agents coupled to IgE loading, 220–221
  See also IgE in cancer therapy

Mouse mammary tumor virus (MMTV), 168–169

MOv18
  IgE-mediated tumor responses
    anti-tumoral responses, 195
    chimeric ovarian carcinoma, 195
    IgE-mediated tumor killing mechanisms
      ADCC, 197, 199
      ADCP, 199–202
  See also Effector cell responses; Trastuzumab like IgE
mRNA
Ig mRNA processing
IgA, 25
IgE, 26
IgG, 25
IgM, 25
membrane form, 24–26
secreted form, 24–26
See also IgE
Mucosal mast cells (MMC), 138–139
See also Connective tissue mast cells (CTMC)
Multiple myeloma, 116
allergic disorders and hematopoietic malignancies (epidemiological evidence), 116–122
mast cells in, 145
See also Plasmacytoma
Murine
IgE
rat IgE specific for murine CD8, 169–170
specific for antigenic determinant on colorectal carcinoma cells surface, 170–171
specific for gp36 of MMTV, 168–169
specific for human folate binding protein, 171–173
See also Mouse IgE
Murine monoclonal antibodies (mAbs), 18–20
Myelogenous leukemias, 83
See also Lymphocytic leukemias
Myeloma, see Multiple myeloma
N
Natural IgE antibodies, 37
See also Low-affinity IgE antibodies
Natural killer (NK) cells
IgE cancer therapy and, 165
IgE effector cells in cancer and, 193
Negative feedback function (CD23), 20–22
Nervous system tumors
epidemiological evidence of allergic disorders and cancer occurrence, 60, 62–64
See also Acoustic neuroma; Brain tumors; Neuroblastoma
Neuroblastoma
epidemiological evidence of allergic disorders and cancer occurrence, 64
See also Acoustic neuroma
Non-Hodgkin lymphoma (NHL)
allergic disorders and epidemiological evidence of, 96–112
case control studies, 98–112
hematopoietic malignancies, 122
chimeric IgE targeting human CD20 and, 174–175
See also Hodgkin lymphoma (NHL)
O
Omalizumab
cancer therapy and, 162–163
See also IgE in cancer therapy
Ovarian cancer
antigen-specific MOv18 in IgE-mediated anti-tumoral responses, 195
epidemiological evidence of allergic disorders and cancer occurrence, 65–66
P
Pancreatic cancer
epidemiological evidence of allergic disorders and cancer occurrence, 56–60
IgE-mediated anti-tumor responses, 205
Paratopes
crosslinking (antigens) and, 232
See also Mimotopes
Pathogen-associated molecular patterns (PAMPs), 238
See also Allergen-associated molecular patterns (AAMP); Tumor-associated molecular patterns
Peripheral blood mononuclear cells (PBMC) in IgE-mediated anti-tumoral responses, 194
See also Effector cell responses
Pirquet’s allergy, see under Allergy
Plasma, 26
Plasma cell malignancies
allergic disorders and epidemiological evidence of, 113, 116–122
multiple myeloma, 116
plasmacytoma, 116
See also Cancers
Plasmablasts
IgE plasmablasts contribution to long-lived plasma cell pool, 26–27
migratory, 26–27
See also Humoral immunological memory
Plasmacytoma, 116
See also Multiple myeloma
Polyadenylation

cleavage-polyadenylation specificity factor (CPSF), 25
external, 26
impaired splicing and polyadenylation restricting mature mIgE transcript generation, 24–26
internal, 24
See also Epsilon-HC gene

Prostate cancer
epidemiological evidence of allergic disorders and cancer occurrence, 65–66
See also Reproductive cancers

Reaginic antibodies, 4
and local anti-tumor anaphylaxis, 166–167
See also IgE in cancer therapy

Recombination, see Class switch recombination (CSR)

Replication protein A (RPA), 18

Reproductive cancers
epidemiological evidence of allergic disorders and cancer occurrence, 65–66
See also Cancers; Anti-tumor

Secreted form mRNA, 24–26

Sequential switching
high-affinity IgE antibodies generation (experimental evidence)
IgGl+ B cells generating IgE antibodies by sequential switching, 43
interleukin-21 inhibiting sequential switching of IgGl+ cells to IgE, 43–44
See also Class switch recombination (CSR)

Serum immunoglobulins
half life, 18–20
serum IgE, 18–20
serum IgG, 19–20

Skin cancer, 68
epidemiological evidence of allergic disorders and cancer occurrence, 68
melanoma, 68
nonmelanoma, 68

Smokers
allergy lung cancer in non-smokers, 54
esophageal cancer and cigarette, 67

See also AllergoOncology (epidemiological evidence of allergic disorders and cancer occurrence); Asthma

Somatic hypermutation, 37
high-affinity IgE antibodies generation, 42–43
See also Affinity maturation

Splicing
impaired splicing and polyadenylation restricting mature mIgE transcript generation, 24–26
See also Polyadenylation

Stomach cancer, 67

Switching
high-affinity IgE antibodies generation aspects (sequential switching to IgE in mice and humans), 40
low-affinity IgE antibodies generation aspects
class switching, 39
direct switching from IgM to IgE, 38

T cell interactions
mast cells and, 141–142
Th2-mediated and anti-tumor immunity
CD4+ T cells (Th1 and Th2 paradigm in tumor biology), 256–257
CD8+ T cells (Tc2 cells), 267–268

T–B cell interactions, 37–38
IgE+ cells found outside GC in both T/B monoclonal mice (T-Bmc) and wild-type mice, 42
See also High-affinity IgE antibodies

cells (Th2-mediated and anti-tumor immunity), 267–268

Testicular cancer, 65

Th17 cells
and B-cell NHL (IgE-mediated allergies), 126–128
See also Cancers

Th2-mediated anti-tumor immunity, 255
alternatively activated macrophages, 264–265

B cells, 266
CD4+ T cells (Th1 and Th2 paradigm), 256–257
eosinophils and eosinophil-derived mediators, 262–264

IgE, 265–266
IgG, 265–266
mas cells and mast-cell mediators, 266–267
Tc2 cells, 267–268
Th2 cytokines, 257
IL-13, 258, 260
IL-24, 258, 261
IL-25, 258, 261–262
IL-4, 257–260
Transmembrane domain, 22
Trastuzumab, 175
Trastuzumab like IgE, 202–203
IgE-mediated tumor killing mechanisms (ADCP), 202
See also Effector cell responses; MOv18
Tumor allergy, 4
mechanism, 6
See also AllergoOncology; Cancers
Tumor-associated macrophages (TAMs), 191–192, 264
Tumor-associated molecular patterns, 242
See also Allergen-associated molecular patterns (AAMP);
Pathogen-associated molecular patterns (PAMPs)

U
Urothelial cancer, 67
Uterine cancer
epidemiological evidence of allergic disorders and cancer occurrence, 65–66
See also Reproductive cancers

V
Vaccination
endogenous IgE response via mimotope vaccination, 175–176
See also IgE adjuvant effect (tumor vaccination); IgE in cancer therapy
Vaccinia virus (VV)
as cell killing agents coupled to IgE loading in mice, 220–221
See also Modified vaccinia virus Ankara (MVA)